Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation [Yahoo! Finance]
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit